MCID: BRN032
MIFTS: 45

Brain Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Glioma

MalaCards integrated aliases for Brain Glioma:

Name: Brain Glioma 12 15
Intracranial Glioma 70
Lower Grade Glioma 12
Glioma of Brain 29

Classifications:



External Ids:

Disease Ontology 12 DOID:0060108
UMLS 70 C3665419

Summaries for Brain Glioma

Disease Ontology : 12 A brain cancer that has material basis in glial cells.

MalaCards based summary : Brain Glioma, also known as intracranial glioma, is related to oligoastrocytoma and oligodendroglioma. An important gene associated with Brain Glioma is TP73-AS1 (TP73 Antisense RNA 1), and among its related pathways/superpathways are Pathways in cancer and Proteoglycans in cancer. The drugs Carmustine and Cobalt have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are cellular and mortality/aging

Related Diseases for Brain Glioma

Diseases related to Brain Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 31.2 MGMT GFAP
2 oligodendroglioma 31.1 VEGFA TP53 MGMT GFAP EGFR
3 high grade glioma 31.1 VEGFA TP53 NES MGMT GFAP EGFR
4 glioblastoma 30.7 VEGFA TP73-AS1 TP53 NES MIR34A MGMT
5 suppression of tumorigenicity 12 30.7 VEGFA TP53 EGFR
6 malignant astrocytoma 30.6 VEGFA TP53 NOTCH1 NES MGMT GFAP
7 brain cancer 30.5 VEGFA TP53 NOTCH1 NES MGMT GFAP
8 pilocytic astrocytoma 30.5 TP53 NES MGMT GFAP
9 pleomorphic xanthoastrocytoma 30.5 TP53 MGMT MAP2 GFAP
10 anaplastic astrocytoma 30.5 VEGFA TP53 NOTCH1 NES MGMT GFAP
11 cellular ependymoma 30.5 NES MGMT GFAP EGFR
12 ganglioglioma 30.5 TP53 NES MAP2 GFAP
13 mixed glioma 30.5 TP53 NES MGMT GFAP EGFR
14 melanoma, uveal 30.5 VEGFA TP53 EZH2 EGFR
15 hydrocephalus 30.4 VEGFA TP53 NOTCH1 NES GFAP
16 colon adenocarcinoma 30.4 VEGFA TP53 NOTCH1 FASLG EGFR
17 meningioma, familial 30.3 VEGFA TP53 MIR34A GFAP EGFR
18 lung cancer susceptibility 3 30.1 VEGFA TP53 PCAT29 EGFR DRAIC
19 melanoma 30.1 VEGFA TP53 PAX3 MIR34A MGMT FASLG
20 b-cell lymphoma 30.1 TP53 STAT6 MIR34A MGMT EZH2
21 bladder cancer 29.7 VEGFA TP53 PCAT29 MIR34A EZH2 EGFR
22 neuroblastoma 29.6 VEGFA TP53 NOTCH1 NES MIR34A MAP2
23 brain glioblastoma multiforme 11.0
24 brain oligodendroglioma 11.0
25 brain ependymoma 11.0
26 glioma 11.0
27 glial tumor 11.0
28 central nervous system immature teratoma 10.5 NES GFAP
29 anaplastic ganglioglioma 10.5 NES GFAP
30 cerebral neuroblastoma 10.5 NES GFAP
31 splenic diffuse red pulp small b-cell lymphoma 10.5 TP53 NOTCH1
32 central nervous system rhabdomyosarcoma 10.5 PAX3 MGMT
33 esophagus verrucous carcinoma 10.5 TP53 EGFR
34 frontal lobe neoplasm 10.5 TP53 MGMT EGFR
35 pediatric angiosarcoma 10.5 VEGFA TP53
36 urethra transitional cell carcinoma 10.5 TP53 GFAP
37 soft tissue sarcoma 10.5 VEGFA TP53 EGFR
38 benign pleural mesothelioma 10.5 TP53 STAT6
39 esophageal basaloid squamous cell carcinoma 10.5 TP53 EGFR
40 primary peritoneal carcinoma 10.5 VEGFA TP53 EGFR
41 bone squamous cell carcinoma 10.5 TP53 NOTCH1 EGFR
42 gliofibroma 10.5 TP53 MGMT GFAP
43 central nervous system primitive neuroectodermal neoplasm 10.5 TP53 NES GFAP
44 mixed oligodendroglioma-astrocytoma 10.5 TP53 MGMT CD276
45 lung adenoma 10.4 TP53 NOTCH1 EGFR
46 tonsil cancer 10.4 TP53 NOTCH1 EGFR
47 pleural cancer 10.4 VEGFA TP53 EGFR
48 lung benign neoplasm 10.4 TP53 MGMT EGFR
49 oropharynx cancer 10.4 TP53 NOTCH1 EGFR
50 mucinous adenocarcinoma 10.4 VEGFA TP53 EGFR

Graphical network of the top 20 diseases related to Brain Glioma:



Diseases related to Brain Glioma

Symptoms & Phenotypes for Brain Glioma

MGI Mouse Phenotypes related to Brain Glioma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 BMP4 EGFR EZH2 FASLG GFAP NOTCH1
2 mortality/aging MP:0010768 10.3 BMP4 EGFR EZH2 FASLG GFAP MAP2
3 endocrine/exocrine gland MP:0005379 10.29 BMP4 EGFR EZH2 FASLG MAP2 MGMT
4 digestive/alimentary MP:0005381 10.19 BMP4 EGFR FASLG GFAP NOTCH1 PAX3
5 integument MP:0010771 10.19 BMP4 EGFR EZH2 FASLG NOTCH1 PAX3
6 embryo MP:0005380 10.18 BMP4 EGFR EZH2 NOTCH1 PAX3 PLK1
7 nervous system MP:0003631 10.18 BMP4 EGFR EZH2 FASLG GFAP MAP2
8 neoplasm MP:0002006 10.1 EGFR EZH2 FASLG MGMT NOTCH1 PAX3
9 liver/biliary system MP:0005370 10.08 BMP4 EGFR FASLG NOTCH1 PAX3 STAT6
10 muscle MP:0005369 10.03 BMP4 EGFR EZH2 GFAP NOTCH1 PAX3
11 normal MP:0002873 9.91 BMP4 EGFR EZH2 FASLG GFAP NOTCH1
12 no phenotypic analysis MP:0003012 9.87 BMP4 EGFR EZH2 MGMT PAX3 TP53
13 renal/urinary system MP:0005367 9.85 BMP4 EGFR EZH2 FASLG NOTCH1 PAX3
14 respiratory system MP:0005388 9.65 BMP4 EGFR EZH2 FASLG MGMT NOTCH1
15 vision/eye MP:0005391 9.28 BMP4 EGFR FASLG GFAP NOTCH1 PAX3

Drugs & Therapeutics for Brain Glioma

Drugs for Brain Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
3
Mitolactol Investigational Phase 3 10318-26-0
4 Alkylating Agents Phase 3
5 Trace Elements Phase 3
6 Nutrients Phase 3
7 Micronutrients Phase 3
8
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
9
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
10
Thioguanine Approved Phase 2 154-42-7 2723601
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Mirtazapine Approved Phase 2 85650-52-8, 61337-67-5 4205
13
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
14
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
15
Memantine Approved, Investigational Phase 2 19982-08-2 4054
16
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
17
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
18
Citalopram Approved Phase 2 59729-33-8 2771
19
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
20
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
21
Tryptophan Approved, Nutraceutical, Withdrawn Phase 2 73-22-3 6305
22
Dexetimide Withdrawn Phase 2 21888-98-2
23 Analgesics, Non-Narcotic Phase 2
24 Analgesics Phase 2
25 Cyclooxygenase Inhibitors Phase 2
26 Cyclooxygenase 2 Inhibitors Phase 2
27 Anti-Inflammatory Agents Phase 2
28 Antimetabolites Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 2
30 Anti-Anxiety Agents Phase 2
31 Adrenergic Agents Phase 2
32 Immunoglobulins Phase 1, Phase 2
33 Antibodies Phase 1, Phase 2
34 Vaccines Phase 2
35 Adrenergic Antagonists Phase 2
36 Adrenergic alpha-Antagonists Phase 2
37 Serotonin 5-HT3 Receptor Antagonists Phase 2
38 Histamine Antagonists Phase 2
39
Histamine Phosphate Phase 2 51-74-1 65513
40 Histamine H1 Antagonists Phase 2
41 Dopamine Agents Phase 2
42 Excitatory Amino Acid Antagonists Phase 2
43 Angiogenesis Inhibitors Phase 1, Phase 2
44 Psychotropic Drugs Phase 2
45 Neurotransmitter Agents Phase 2
46 Parasympatholytics Phase 2
47 Cholinergic Antagonists Phase 2
48 Cholinergic Agents Phase 2
49 Antiparkinson Agents Phase 2
50 Muscarinic Antagonists Phase 2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
2 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
3 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
4 Carbon-11-Sodium Acetate Positron Emission Tomography/Computed Tomography (PET/CT) Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression Withdrawn NCT01961934 Phase 2, Phase 3 Sodium Acetate C11 PET/CT Imaging
5 Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor Unknown status NCT02617134 Phase 1, Phase 2
6 A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion Unknown status NCT01534845 Phase 2 Temozolomide (Temodal)
7 Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma Completed NCT00870181 Phase 2 systemic chemotherapy
8 Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme Completed NCT00504660 Phase 2 Capecitabine;Celecoxib (Celebrex);Temozolomide;Lomustine;6-Thioguanine
9 Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification) Recruiting NCT04623931 Phase 2 Temozolomide
10 A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse Recruiting NCT03779230 Phase 1, Phase 2 L19TNF
11 A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 Recruiting NCT03650257 Phase 2 Temozolomide
12 Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy Recruiting NCT03935685 Phase 2 Mirtazapine (Remeron)
13 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Recruiting NCT03194906 Phase 2 Memantine
14 Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
15 A Pilot Study Utilizing Escitalopram to Address Cognitive Dysfunction in Glioma Patients Suspended NCT03728673 Phase 2 Escitalopram Oral Tablet
16 Phase II Study of Panitumumab in Combination With Irinotecan for Malignant Gliomas Terminated NCT01017653 Phase 2 Irinotecan;Panitumumab
17 Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma Withdrawn NCT04406610 Phase 1, Phase 2
18 Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurrent Malignant Glioma Completed NCT01550523 Phase 1 IGF-1R/AS ODN
19 Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate Recruiting NCT04540107 Phase 1 Hyperpolarized Carbon C 13 Pyruvate
20 A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide Recruiting NCT03152318 Phase 1 rQNestin;Cyclophosphamide
21 A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma Recruiting NCT01904123 Phase 1 STAT3 Inhibitor WP1066
22 A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma Suspended NCT03011671 Phase 1 Acetazolamide;Temozolomide
23 IRDye800CW-BBN PET-NIRF in Lower Grade Glioma Unknown status NCT03407781 Early Phase 1 68Ga-BBN-IRDye800CW
24 Pilot Study: Measure of the Potential Evoked With Electroencephalography and Electrocorticography by Electric Stimulation of the Brain During the Neurosurgery Awakened of the Infiltrative Glioma of Low Grade (OMS Type II) Unknown status NCT02509442
25 Noninvasively Predicting Isocitrate Dehydrogenase Gene Status in Glioma by Amide Proton Transfer Imaging Unknown status NCT03102112
26 A Pilot Randomized Controlled Trial on the Feasibility and Efficacy of an Exercise Intervention to Improve Cognitive Functioning in Patients With Glioma Completed NCT02303938
27 The Effects of Mild Sedation on Compensatory Upper Limb Motor Function Networks Based on Multimodal Magnetic Resonance Imaging in With Gliomas in Brain Eloquent Areas Recruiting NCT03984240 Midazolam;Dexmedetomidine
28 Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas Recruiting NCT03948490
29 Are Gliomas in Adults Associated With a Unique Identifying Blood Biomarker Signature? Recruiting NCT03698201
30 A New Strategy for the Visulation of Molecular Genotype in Glioma Evolution Based on the Radiomics and Microomics Recruiting NCT03750890
31 Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients and Setting up a Large-scale, Prospective Database for Glioma Patients Treated in UZ Leuven Recruiting NCT03849430
32 A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy Recruiting NCT03927274 Early Phase 1 Topotecan
33 Efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma: A Prospective Exploratory Clinical Study Recruiting NCT03949192
34 Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors Recruiting NCT03154801
35 Randomized Control Trial for Awake vs. Asleep Craniotomy for Non-eloquent Gliomas Recruiting NCT03621748
36 Registry Describing Clinical Information, Conventional, and Advanced Magnetic Resonance Imaging Information of Patients With Brain Glioma Recruiting NCT02619890
37 Survival Significance and Clinical Characteristics of Molecular Pathology and Genetic Variation in Brain Gliomas Recruiting NCT04216537
38 Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases Recruiting NCT04111588
39 Feasibility of the LUM Imaging System for In Vivo and Ex Vivo Detection of Cancer in Subjects With Low Grade Gliomas, Glioblastomas, and Cancer Metastases to the Brain Active, not recruiting NCT03717142
40 Glioma Microenvironment an Exploratory Study Active, not recruiting NCT03189420
41 Early Post-surgical Temozolomide Therapy in Patients With High-Grade Gliomas Admitted to Acute Rehabilitation: A Feasibility Study Not yet recruiting NCT03796507 Early Phase 1 Temozolomide
42 The Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier Not yet recruiting NCT04063514
43 CSMC IIT: Pilot Study of Phosphodiesterase-V Inhibition to Increase Intratumoral Concentration of Carboplatin in Patients With Recurrent High Grade Gliomas and Brain Metastases Terminated NCT02279992 Early Phase 1 Vardenafil;Carboplatin
44 Laser Interstitial Thermal Therapy (LITT) as Palliative Treatment for Patients With Malignant Glioma Requiring Standard Treatment Alternatives Withdrawn NCT03176160

Search NIH Clinical Center for Brain Glioma

Genetic Tests for Brain Glioma

Genetic tests related to Brain Glioma:

# Genetic test Affiliating Genes
1 Glioma of Brain 29

Anatomical Context for Brain Glioma

MalaCards organs/tissues related to Brain Glioma:

40
Brain, Breast, Lung, Bone, Spinal Cord, T Cells, Tongue

Publications for Brain Glioma

Articles related to Brain Glioma:

(show top 50) (show all 893)
# Title Authors PMID Year
1
Magnetic resonance imaging evaluation of brain glioma before postoperative radiotherapy. 61
32857338 2021
2
T cell immune regulator 1 is a prognostic marker associated with immune infiltration in glioblastoma multiforme. 61
33664816 2021
3
A novel image signature-based radiomics method to achieve precise diagnosis and prognostic stratification of gliomas. 61
32829381 2021
4
Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication. 61
33025175 2021
5
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy. 61
33811494 2021
6
A NIR fluorescent smart probe for imaging tumor hypoxia. 61
33811473 2021
7
A hybrid approach based on multiple Eigenvalues selection (MES) for the automated grading of a brain tumor using MRI. 61
33581624 2021
8
Prediction of ATPase cation transporting 13A2 molecule in Petromyzon marinus and pan-cancer analysis into human tumors from an evolutionary perspective. 61
33743014 2021
9
Gamma Knife Radiosurgery for High-Grade Gliomas: Single-Center Experience of Six Years in China. 61
33756470 2021
10
Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients. 61
33761371 2021
11
Simultaneously acquired PET and ASL imaging biomarkers may be helpful in differentiating progression from pseudo-progression in treated gliomas. 61
33787971 2021
12
Epilepsy enhance global efficiency of language networks in right temporal lobe gliomas. 61
33464718 2021
13
Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. 61
32840682 2021
14
Automated MRI based pipeline for segmentation and prediction of grade, IDH mutation and 1p19q co-deletion in glioma. 61
33482430 2021
15
Biodistribution and radiation dosimetry of D-isomer of 4-borono-2-[18F]fluoro-phenylalanine: A comparative PET/CT study with L-isomer in healthy human volunteers. 61
33486437 2021
16
Immune-related genes with APA in microenvironment indicate risk stratification and clinical prognosis in grade II/III gliomas. 61
33665000 2021
17
CANet: Context Aware Network for Brain Glioma Segmentation. 61
33720830 2021
18
Follow-up of a Rickettsia felis encephalitis: Some new insights into clinical and imaging features. 61
33444751 2021
19
Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion. 61
33631386 2021
20
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. 61
33622704 2021
21
High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. 61
33645009 2021
22
Hypermutated phenotype in gliosarcoma of the spinal cord. 61
33580181 2021
23
Neuropsychological Function and Quality of Life after Resection of Suspected Lower-Grade Glioma in the Face Primary Motor Area. 61
33557128 2021
24
Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines. 61
33572092 2021
25
Quantitative Features From CHO PET Distinguish the WHO Grades of Primary Diffuse Glioma. 61
33208625 2021
26
Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA. 61
33454543 2021
27
N-(2-18F-fluoropropionyl)-l-glutamate as a potential oncology tracer for PET imaging of glioma. 61
33285464 2021
28
The Role of Surgery in IDH-Wild-Type Lower-Grade Gliomas: Threshold at a High Extent of Resection Should be Pursued. 61
33647953 2021
29
Prognostic model and nomogram construction based on autophagy signatures in lower grade glioma. 61
32519365 2021
30
Prognostic and immunological role of Fam20C in pan-cancer. 61
33306121 2021
31
Navigated Transcranial Magnetic Stimulation Motor Mapping Usefulness in the Surgical Management of Patients Affected by Brain Tumors in Eloquent Areas: A Systematic Review and Meta-Analysis. 61
33746895 2021
32
Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors. 61
33498680 2021
33
Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression. 61
33532725 2021
34
Developing a lncRNA Signature to Predict the Radiotherapy Response of Lower-Grade Gliomas Using Co-expression and ceRNA Network Analysis. 61
33767991 2021
35
Prognostic Value of an Autophagy-Related Five-Gene Signature for Lower-Grade Glioma Patients. 61
33768004 2021
36
Uncertainty modelling in deep learning for safer neuroimage enhancement: Demonstration in diffusion MRI. 61
33039617 2021
37
DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival. 61
33498463 2021
38
EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma. 61
33545987 2021
39
FOXG1 mediates the radiosensitivity of glioma cells through regulation of autophagy. 61
33201747 2021
40
Sex Differences in Time to Treat and Outcomes for Gliomas. 61
33680971 2021
41
CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma. 61
33465115 2021
42
A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment. 61
33069830 2021
43
IKBIP is a novel EMT-related biomarker and predicts poor survival in glioma. 61
33552590 2021
44
Antioxidant, Anti-Inflammatory and Cytotoxic Properties of Centaurea africana Lamk var. [Bonnet] M]. 61
32516104 2021
45
Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading. 61
33410948 2021
46
CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma. 61
33479027 2021
47
The diagnostic and prognostic values of microRNA-196a in cancer. 61
33289788 2021
48
CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis. 61
33680972 2021
49
Prognostic value and immunological role of PDCD1 gene in pan-cancer. 61
33069926 2020
50
Conditional reprograming culture conditions facilitate growth of lower grade glioma models. 61
33258947 2020

Variations for Brain Glioma

Expression for Brain Glioma

Search GEO for disease gene expression data for Brain Glioma.

Pathways for Brain Glioma

Pathways related to Brain Glioma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.22 VEGFA TP53 STAT6 NOTCH1 FASLG EGFR
2 12.16 VEGFA TP53 FASLG EGFR
3
Show member pathways
12.16 VEGFA TP53 MAP2 EGFR
4 12.12 VEGFA TP53 NOTCH1 MIR34A EZH2 EGFR
5 11.95 VEGFA TP53 PLK1 EGFR
6 11.86 VEGFA NOTCH1 NES BMP4
7 11.75 TP53 SLIT2 GFAP EGFR
8 11.68 VEGFA TP53 STAT6 FASLG
9 11.6 VEGFA TP53 EGFR
10 11.57 PAX3 NOTCH1 GFAP BMP4
11 11.41 TP53 FASLG EGFR
12 11.39 VEGFA TP53 FASLG
13 11.35 VEGFA NOTCH1 BMP4
14 11.32 VEGFA NOTCH1 BMP4
15 11.14 VEGFA STAT6 EGFR
16 11.06 VEGFA NOTCH1 NES MAP2 GFAP EZH2

GO Terms for Brain Glioma

Biological processes related to Brain Glioma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.14 VEGFA SLIT2 PAX3 NOTCH1 NES EGFR
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 VEGFA TP53 STAT6 PAX3 NOTCH1 EGFR
3 positive regulation of gene expression GO:0010628 10.04 VEGFA TP53 NOTCH1 MIR34A BMP4
4 positive regulation of cell proliferation GO:0008284 10 VEGFA NOTCH1 FASLG EZH2 EGFR BMP4
5 positive regulation of apoptotic process GO:0043065 9.97 TP53 SLIT2 NOTCH1 FASLG BMP4
6 negative regulation of apoptotic process GO:0043066 9.97 VEGFA TP53 PLK1 MGMT EGFR BMP4
7 positive regulation of cell migration GO:0030335 9.95 VEGFA NOTCH1 EGFR BMP4
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 VEGFA NOTCH1 EGFR BMP4
9 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 VEGFA TP53 STAT6 PLK1 NOTCH1 FASLG
10 regulation of cell proliferation GO:0042127 9.91 TP53 STAT6 NOTCH1 EZH2
11 negative regulation of cell death GO:0060548 9.8 NOTCH1 MGMT BMP4
12 positive regulation of MAP kinase activity GO:0043406 9.76 VEGFA EZH2 EGFR
13 outflow tract morphogenesis GO:0003151 9.74 VEGFA NOTCH1 BMP4
14 lung development GO:0030324 9.73 VEGFA NOTCH1 EGFR BMP4
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.71 NOTCH1 EZH2 BMP4
16 positive regulation of epithelial cell proliferation GO:0050679 9.67 VEGFA NOTCH1 EGFR BMP4
17 cardiac septum morphogenesis GO:0060411 9.66 TP53 NOTCH1
18 protein localization to chromatin GO:0071168 9.65 PLK1 EZH2
19 epithelial to mesenchymal transition involved in endocardial cushion formation GO:0003198 9.65 NOTCH1 BMP4
20 aortic valve morphogenesis GO:0003180 9.65 SLIT2 NOTCH1 BMP4
21 tube formation GO:0035148 9.64 VEGFA NOTCH1
22 endocardial cushion development GO:0003197 9.63 NOTCH1 BMP4
23 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.63 VEGFA NOTCH1
24 negative regulation of gene expression GO:0010629 9.63 VEGFA TP53 NOTCH1 MIR34A EZH2 BMP4
25 coronary artery morphogenesis GO:0060982 9.61 VEGFA NOTCH1
26 pulmonary valve morphogenesis GO:0003184 9.58 SLIT2 NOTCH1 BMP4
27 regulation of cell cycle G2/M phase transition GO:1902749 9.56 TP53 PLK1
28 negative regulation of smooth muscle cell chemotaxis GO:0071672 9.55 SLIT2 MIR34A
29 cardiac vascular smooth muscle cell development GO:0060948 9.51 VEGFA NOTCH1
30 coronary vein morphogenesis GO:0003169 9.46 VEGFA NOTCH1
31 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR BMP4
32 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.13 VEGFA TP53 NOTCH1
33 branching morphogenesis of an epithelial tube GO:0048754 8.92 VEGFA SLIT2 NOTCH1 BMP4

Molecular functions related to Brain Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 VEGFA TP53 STAT6 SLIT2 PLK1 NOTCH1
2 protein phosphatase binding GO:0019903 9.13 TP53 STAT6 EGFR

Sources for Brain Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....